A Synthetic ERRα Agonist Induces an Acute AerobicExercise Response and Enhances Exercise Capacity

Billon, C.; Banerjee, S.; Situala, S.; Welch, R.; Hegazy, L.; Elgendy, B.; Oh, T. G.; Kazantzis, M.; Chatterjee, A.; Chrivia, J.; Hayes, M.; Xu, W.; Hamilton, A.; Huss, J.; Zhang, L.; Walker, J. K.; Downes, M.; Evans, R.; Burris, T.

doi:10.1101/2022.10.05.510974

bioRxiv · 10.1101/2022.10.05.510974

A Synthetic ERRα Agonist Induces an Acute AerobicExercise Response and Enhances Exercise Capacity

Billon, C.·Banerjee, S.·Situala, S.·Welch, R.·Hegazy, L.·Elgendy, B.·Oh, T. G.·Kazantzis, M.·Chatterjee, A.·Chrivia, J.·Hayes, M.·Xu, W.·Hamilton, A.·Huss, J.·Zhang, L.·Walker, J. K.·Downes, M.·Evans, R.·Burris, T.

View original source ↗Export metadata ↓

Abstract

Repetitive physical exercise induces physiological adaptations in skeletal muscle that improves exercise performance and is effective for the prevention and treatment of several diseases. Here we report the identification of a synthetic agonist for the orphan nuclear receptor ERR (estrogen receptor-related receptor ), SLU-PP-332, that activates an acute aerobic exercise genetic program in skeletal muscle in an ERR-dependent manner. SLU-PP-332 increases mitochondrial function and cellular respiration consistent with induction of this genetic program. When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise endurance. These data indicate the feasibility of targeting ERR for development of compounds that act as exercise mimetics that may be effective in treatment of numerous metabolic disorders and to improve muscle function in the aging.

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Billon, C., Banerjee, S., Situala, S., Welch, R., Hegazy, L., Elgendy, B., Oh, T. G., Kazantzis, M., Chatterjee, A., Chrivia, J., Hayes, M., Xu, W., Hamilton, A., Huss, J., Zhang, L., Walker, J. K., Downes, M., Evans, R., Burris, T.. 2022-10-07. A Synthetic ERRα Agonist Induces an Acute AerobicExercise Response and Enhances Exercise Capacity. https://doi.org/10.1101/2022.10.05.510974

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

bioRxiv2023

A machine learning approach to predict drug-induced autoimmunity using transcriptional data.

Drug-induced autoimmunity (DIA) is an idiosyncratic adverse drug reaction. Although first reported in the mid-1940s, the mechanisms underlying DIA remain unclear, and there is little understanding of why it is only associated with some drugs. Because it only occurs in a small number of patients, DIA is not normally detected until a drug has reached the market. We describe an ensemble machine learning approach using transcriptional data to predict DIA. The genes comprising the signature implicate dysregulation of cell cycling or proliferation as part of the mechanism of DIA. This approach could be adapted by pharmaceutical companies as an additional preclinical safety screen, reducing the risk of drugs with the potential to cause autoimmunity reaching the market.

pharmacology and toxicology↗